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Abstract
Background: Hypoxia-inducible factor (HIF) is an attractive therapeutic target for renal cell carcinoma (RCC) as its high
expression due to the loss of von Hippel-Lindau (VHL) promotes RCC progression. Considering this, we hypothesized that
ELR510444, a novel orally available small molecule inhibitor of HIF activity, would reduce angiogenesis and possess
significant activity in RCC. The mechanism of action and therapeutic efficacy of ELR510444 were investigated in in vitro and
in vivo models of RCC.
Principal Findings: ELR510444 decreased HIF-1a and HIF-2a levels, reduced RCC cell viability and clonogenic survival, and
induced apoptosis. VHL-deficient RCC cells were more sensitive to ELR510444-mediated apoptosis and restoration of VHL
promoted drug resistance. Higher concentrations of ELR51044 promoted apoptosis independently of VHL status, possibly
due to the microtubule destabilizing properties of this agent. ELR510444 significantly reduced tumor burden in the 786-O
and A498 RCC xenograft models. These effects were associated with increased necrosis and apoptosis and inhibition of
angiogenesis.
Conclusions: ELR510444 is a promising new HIF inhibitor that reduced RCC cell viability, induced apoptosis, and diminished
tumor burden in RCC xenograft models. ELR510444 also destabilized microtubules suggesting that it possesses vascular
disrupting and anti-angiogenic properties. Further investigation of ELR510444 for the therapy of RCC is warranted.
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Introduction
Overexpression of the hypoxia inducible factors (HIFs) HIF-1a or
HIF-2a is associated with cancer progression [1,2,3,4,5,6]. HIF-1 is a
heterodimer composed of HIF-1a and HIF-1b subunits and HIF-2
consistsofHIF-2aand HIF-1bsubunits.HIF-1bor aryl hydrocarbon
nuclear translocator (ARNT) is constitutively expressed and HIF
activity is regulated by the expression of the a subunits [7]. The
development of new blood vessels from the pre-existing vasculature
(angiogenesis) is an essential process required for cancer progression.
Under low oxygen conditions, the consequential upregulation of
HIFs promote the increased expression of genes involved in
angiogenesis (vascular endothelial growth factor, VEGF), metabolism
(Glut-1), drug resistance (MDR-1), and cell survival (Bcl-2) [8,9,10].
Strategies that inhibit angiogenesis have become a viable therapeutic
approach for many tumor types. VEGF is a major regulator of
angiogenesis and antagonizing its function with the monoclonal
antibody bevacizumab (Avastin) has demonstrated antitumor efficacy
in preclinical models and in clinical trials [11,12].
The multi-tyrosine kinase inhibitors sunitinib and sorafenib and
the mTOR inhibitors temsirolimus/CCI-779 and everolimus/
RAD001 have demonstrated efficacy for the treatment of renal cell
carcinoma (RCC). The activity of these agents against RCC has
been partially attributed to their ability to inhibit angiogenesis
[12,13]. Despite the success of these agents, drug resistance
continues to be an obstacle, which underscores the need for new
treatment strategies to improve clinical outcomes.
Mutations or loss of the von Hippel-Lindau (VHL) tumor
suppressor gene are a frequent occurrence in RCC [14]. VHL is
an E3 ubiquitin ligase that targets the a subunit of HIF for
degradation via the proteasome. Loss of VHL expression results in
the stabilization of HIFs and occurs in 70% of sporadic clear cell
RCC patients [15]. In VHL-deficient cells, HIFs are constitutively
active and induce target genes that promote tumor progression [16].
Consistent with the role of HIF in cancer, introduction of VHL into
VHL-deficient RCCs suppresses tumor formation in mice [17].
Given this, targeting HIF activity may be a promising strategy to treat
RCC and other malignancies with elevated HIF transcription rates.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e31120ELR510444 is a novel, orally available small molecule HIF
inhibitor that has been developed by ELARA Pharmaceuticals.
Here we report that ELR510444 decreases HIF-1a and HIF-2a
expression in RCC cells and cells deficient in VHL are
hypersensitive to ELR510444-mediated apoptosis. ELR510444
also displayed significant efficacy in two RCC xenograft models in
vivo. In addition, our findings demonstrate that higher concentra-
tions of ELR510444 destabilize microtubules, suggesting that this
agent has vascular disrupting properties. This is evident in tumors
treated with ELR510444, which show enhanced central tumor
necrosis along with diminished tumor vasculature.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol (930886) was approved by the Institutional Animal Care
and Use Committee (Assurance #A3345-01) at the University of
Texas Health Science Center at San Antonio.
Cells and cell culture
786-O, A498, Caki-1, Caki-2, and Achn renal cancer cell lines
were obtained from the American Type Culture Collection
(Manassas, VA). RCC4 cells were obtained from Dr. Sunil
Sudarshan (University of Texas Health Science Center at San
Antonio). Cell lines were cultured in RPMI supplemented with
10% fetal bovine serum and maintained in a humidified incubator
at 37uC with 5% CO2.
Antibodies and reagents
Antibodies were obtained from the following commercial
sources: anti-VEGF (Santa Cruz Biotechnology, Santa Cruz,
CA); anti-HIF-1a (R&D Systems, Minneapolis, MN); anti-HIF-2a
(Novus Biologicals, Littleton, CO); anti-cleaved caspase-3 (Cell
Signaling, Danvers, MA); anti-b-tubulin (Sigma-Aldrich, St Louis,
MO); anti-CD31 (BD Pharmingen, San Jose, CA); anti-prolifer-
ating cell nuclear antigen (PCNA) (Dako, Glostrup, Denmark);
goat anti-rabbit and goat anti-rat horseradish peroxidase (HRP)-
conjugated secondary antibodies (Jackson Laboratories, West
Grove, PA); Rat anti-mouse IgG2a-HRP (Serotec, Raleigh, NC);
Goat anti-mouse Alexa Fluor 488 and 49,6-diamidino-2-pheny-
lindole (DAPI) (Invitrogen, Carlsbad, CA); and sheep anti-mouse-
HRP and donkey anti-rabbit-HRP (Amersham, Pittsburgh, PA).
ELR510444 was kindly provided by ELARA Pharmaceuticals
GmbH (Heidelberg, Germany). Vincristine, 1-methyl-2-pyrroli-
done, CoCl2, and propidium iodide (PI) were purchased from
Sigma-Aldrich. N,N9-ethylene-bis(iodoacetamide) (EBI) was ob-
tained from TRC Biomedical Research Chemicals (New York,
ON, Canada). Solutol HS15 was purchased from BASF (Florham
Park, NJ). Polyethylene glycol 400 was obtained from Hampton
Research (Aliso Viejo, CA).
Quantification of drug-induced cytotoxicity
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. RCC cells were
seeded in 96-well plates at a density of 10,000 cells per well and
allowed to attach overnight. Cells were treated with varying
concentrations of ELR510444 for 72 h. Cell viability was
determined by incubating the cells in MTT, dissolving MTT in
dimethyl sulfoxide (DMSO), and measuring absorbance using a
BioTek (Winooski, VT) microplate reader. The pro-apoptotic
effects of ELR510444 following 24 h treatment were quantified by
PI staining and fluorescence-activated cell sorting (FACS) analysis
of sub-G0/G1 DNA content as previously described [18].
Clonogenic survival assays
Cells were treated with 3, 10, or 30 nM ELR510444 for 24 h.
After drug treatment, cells were washed twice in PBS followed by
the addition of fresh media and incubated for 10 days in a
humidified incubator at 37uC with 5% CO2. Colonies were then
washed in PBS, fixed with methanol, and stained with crystal
violet. Colonies were counted using an Alpha Innotech (San
Leandro, CA) gel documentation system.
Immunoblotting
RCC cells were treated with ELR510444, collected, and lysed for
1 h on ice in Triton X-100 lysis buffer (1% triton X-100, 150 mM
NaCl, 25 mMTris pH 7.5)with proteaseinhibitors. Approximately
50 mg of total cellular protein from each sample were separated by
SDS-PAGE. Proteins were transferred to nitrocellulose membranes
and blocked with 5% nonfat milk in a Tris-buffered saline solution
containing 0.1% Tween-20 for 1 h. The blots were probed
overnight with the indicated primary antibodies at 4uC, washed,
and then probed with species-specific secondary antibodies coupled
to HRP. Bands were detected by enhanced chemiluminescence
(Alpha Innotech, San Leandro, CA).
HIF-1a activity assay
RCC4 cells were treated for 16 h with various concentrations of
ELR510444. Cells were harvested and lysed on ice using HEPES
lysis buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2,1 0m M
KCl, 0.5 mM DTT) for 30 min followed by nuclear extraction
(20 mM HEPES pH 7.9, 25% glycerol, 450 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA pH 8.0, 0.5 mM DTT) for 30 min. HIF-
1a activity was measured using the HIF-1a transcription factor
assay kit (Cayman Chemical, Ann Arbor, MI) according to the
manufacturer’s instructions. Absorbance was quantified at 450 nm
using a Biotek microplate reader.
Quantitative real time polymerase chain reaction (qRT-
PCR)
RCC4, 786-O and A498 cells were treated with 10 nM
ELR510444 for 24 h. cDNA from Control and ELR510444
treated cells were used for relative quantification by RT–PCR
analyses. First-strand cDNA synthesis was performed from 1 mg
RNA in a 20 ml reaction mixture using the high-capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA).
HIF-1a, HIF-2a (EPAS1), and GAPDH transcripts were amplified
using commercially available TaqMan Gene expression assays
(Applied Biosystems, Foster City, CA). Relative gene expression
was calculated with the 2
2DDCt method using GAPDH as a
housekeeping gene [19].
VEGF ELISA assay
VEGF secretion was measured in RCC cells using Quantikine
ELISA kits (R&D Systems, Inc., Minneapolis, MN). Cells were
plated in 6-well plates and were untreated, treated with 10 nM
ELR510444 or 250 mM CoCl2 for 16 h. Supernatants were
collected and VEGF protein levels were determined by ELISA
according to the manufacturer’s instructions. Absorbances were
measured using a BioTek microplate reader.
VHL transfection into RCC cells
Transfection of VHL into VHL-deficient cells was performed
using the pCMV6-VHL-AC-GFP plasmid. The plasmid is a GFP-
ELR510444 Inhibits HIF Activity
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(OriGene, Rockville, MD) and transformed into One Shot TOP10
chemically competent E. coli (Invitrogen, Carlsbad, CA). After
overnight incubation at 37uC, a single colony was grown in LB
broth with ampicillin. The plasmid was isolated using the Qiagen
mini-prep plasmid isolation kit (Qiagen Inc., Valencia, CA) and
stored at 220uC until ready for transfection. A498 and 786-0 cells
were transfected with 1 mg of pCMV6-VHL-AC-GFP and the
empty vector using the TransFast reagent (Promega, Madison,
WI) according to the manufacturer’s protocol. Positive transfected
clones were selected by serial dilution in the presence of
puromycin.
Immunocytochemistry
RCC4 cells were plated on chamber slides and treated with
ELR510444 or 100 nM vincristine for 24 h. Cells were fixed with
4% paraformaldehyde, permeabilized using 0.2% Triton X-100,
and incubated overnight with b-tubulin antibody. Goat anti-
mouse Alexa 488 fluorescent secondary antibody was used to
visualize microtubules. DAPI was used to counterstain the nucleus.
Images were captured using a Zeiss LSM 510 Meta confocal
microscope with an oil 406objective as previously described [20].
Colchicine-binding site assay. N,N9-ethylene-bis(iodoaceta-
mide) (EBI) crosslinks with the cysteine residues of b-tubulin at
positions 239 and 354, which are associated with the colchicine-
binding site [21]. The occupancy of the colchicine-binding site by
antimitotic drugs, such as ELR510444 disrupts EBI: b-tubulin
adduct formation. The b-tubulin adduct formed migrates faster
than b-tubulin and is detectable by immunoblotting [22]. RCC4
cells were incubated with ELR510444 for 2 h prior to the addition
of 100 mM EBI treatment for 1.5 h. After drug treatment, cells
were processed for immunoblotting and probed with a b-tubulin
antibody.
Xenograft studies
786-O and A498 RCC cells (1610
7) were suspended in a
mixture of HBSS and Matrigel (BD BioSciences, San Jose, CA)
and subcutaneously implanted into female nude mice (BALB/c
background) from Harlan (Indianapolis, IN). Tumor-bearing
animals were randomized into vehicle or ELR510444 treatment
groups. Mice were treated orally with vehicle (10% 1-methyl-2-
pyrrolidone, 20% Solutol HS15, 40% polyethylene glycol 400,
30% water) or 8 mg/kg ELR510444 on a QDx5 (every day for 5
days) schedule for 2 weeks. Mice were monitored daily and tumor
volumes were measured twice weekly. Tumors were harvested at
the end of the study and either formalin-fixed and paraffin-
embedded or OCT-embedded and snap-frozen for immunohisto-
chemical analysis.
Immunohistochemistry
Paraffin-embedded tumor sections were deparaffinized in
xylene, exposed to a graded series of alcohol, and rehydrated in
PBS (pH 7.5). Frozen slides were fixed by exposure to cold
acetone, chloroform and acetone, and acetone again. Heat-
induced epitope retrieval on paraffin-embedded sections was
performed by microwaving slides in a citrate buffer for 5 min.
Endogenous peroxides were blocked with a 3% hydrogen peroxide
solution for 10 min. Slides were then incubated in a protein block
solution (5% horse and 1% goat serum in PBS) for 20 min. PCNA,
cleaved caspase-3, VEGF (paraffin-embedded tumors) or CD31
(frozen slides) antibodies were diluted in the protein block solution
and placed at 4uC overnight. After washing with PBS, slides were
incubated in appropriate secondary antibodies for 1 h at ambient
temperature. Positive reactions were visualized using 3,39-
diaminobenzidine diaminobenzidine (Research Genetics, Hunts-
ville, AL) for 10 min. The slides were rinsed with water followed
by a brief counterstain with Gill’s hematoxylin (Sigma, St. Louis,
MO). Images were captured using an Olympus fluorescent
microscope (Center Valley, PA) with a DP71 camera and a 206
objective. Image-Pro Plus software Version 6.2.1 (MediaCyber-
netics, Bethesda, MD) was used for image acquisition. ImageJ
software was used for quantification of VEGF levels by
densitometric analysis of five random fields containing viable
tumor cells. Quantification of PCNA, cleaved caspase-3, and
CD31 was conducted by counting the number of positive cells in
five random fields.
CD31 and Terminal deoxyribonucleotide-transferase–
mediated dUTP nick-end labeling (TUNEL) assay
Frozen tumor sections were stained with CD31 antibody.
Vessels were visualized by using a Texas Red Goat anti-Rat
secondary antibody. DNA fragmentation was analyzed using a
FITC-labeled TUNEL assay kit (Promega, Madison, WI) and
performed according to the manufacturer’s instructions. Slides
were mounted using Prolong anti-fade reagent (Molecular Probes,
Eugene, OR). Images were captured with an Olympus fluorescent
microscope (Center Valley, PA) with a DP71 camera and a 206
objective. TUNEL-positive cells were determined by manual
counting of 5 random fields per section. Image-Pro Plus software
Version 6.2.1 (MediaCybernetics, Bethesda, MD) was used for
image acquisition.
Statistical analyses
The Tukey-Kramer Comparison Test or the Student’s t test was
used to determine statistical significance. Differences were
considered significant in all experiments at p,0.05.
Results
ELR510444 reduces the expression of HIF-1a, HIF-2a, and
VEGF in RCC cells
HIFs play a key role in tumor progression and are an ideal
target to inhibit angiogenesis. ELR510444 is a novel, orally
available, small molecule inhibitor of HIF activity (Figure 1A).
Treatment with ELR510444 inhibited HIF-1a activity at low nM
concentrations in the VHL-deficient RCC4 cell line (Figure 1A).
Further analysis demonstrated that ELR510444 induced a dose-
dependent decrease in both HIF-1a and HIF-2a protein
expression in RCC4 cells (Figure 1B). 786-O and A498 RCC
cells also lack a functional VHL gene, but unlike RCC4 cells which
express both HIF-1a and HIF-2a, 786-O and A498 cells express
only HIF-2a [23]. Quantitative real-time PCR (qRT-PCR)
analysis also revealed a significant decrease in HIF-1a levels in
RCC4 cells and HIF-2a levels in all 3 VHL-deficient cell lines
following ELR510444 treatment (Figure 1C). Since VEGF is a
major transcriptional target of HIFs, we next evaluated the effects
of ELR510444 on VEGF secretion. Consistent with inhibition of
HIF activity, ELR510444 significantly decreased VEGF levels in
RCC cell lines (Figure 1D).
ELR510444 preferentially induces apoptosis in VHL-
deficient RCC cells
Loss of VHL expression is linked to constitutive HIF activity
and consequentially high levels of VEGF expression. Quantifica-
tion of VEGF levels in VHL
2/2 and VHL
+/+ RCC cell lines
confirmed the relationship between VHL status and VEGF
(Figure 2A). Considering the proposed regulatory role of HIF in
ELR510444 Inhibits HIF Activity
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e31120Figure 1. ELR510444 decreases HIF-1a and HIF-2a expression. (A) ELR510444 (chemical structure on left) inhibits HIF-1a activity. RCC4 cells
were treated with the indicated concentrations of ELR510444 for 16 h. Cells were harvested, nuclei isolated and lysed, and HIF-1a activity was
measured using a commercial activity kit according to the manufacturer’s protocol. Mean 6 SD, n=3. (B) ELR510444 decreases HIF-1a and HIF-2a
protein expression. RCC4 cells were treated with ELR510444 for 24 h and protein levels were measured by immunoblotting. (C) Quantitative real-time
PCR analysis of HIF-1a and HIF-2a (EPAS1) levels. RCC cells were treated with 10 nM ELR510444 for 24 h and gene expression was measured by qRT-
PCR. Mean 6 SD, n=3. *Indicates a significant difference from controls, p,0.05. Note that HIF-1a is not present 786-O and A498 cells. (D) ELR510444
decreases VEGF secretion. RCC cells were treated with 10 nM ELR510444 for 16 h. Media was harvested and VEGF levels were measured by ELISA.
Mean 6 SD, n=3. *Represents a significant difference compared to controls, p,0.05.
doi:10.1371/journal.pone.0031120.g001
ELR510444 Inhibits HIF Activity
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e31120RCC tumorigenesis and drug resistance, we hypothesized that
targeting HIF with ELR510444 would be an effective strategy for
the treatment of RCC. To test our hypothesis, we first evaluated
the activity of ELR510444 in a panel of RCC cell lines. MTT and
clonogenic survival assays demonstrated that ELR510444 exhib-
ited strong activity against all of the RCC lines tested (Figure 2B
and 2C). In addition to reducing cell viability and colony
formation, ELR510444 also stimulated apoptosis in RCC cell
lines (Figure 2D). Interestingly, ELR510444 possessed greater
efficacy against VHL-deficient cancer cells compared to VHL
+/+
cell lines. This effect was most pronounced at the concentration of
10 nM ELR510444, which preferentially induced apoptosis in
VHL
2/2 cell lines (Figure 2D). These data suggested that
ELR510444 may be more efficacious in cell lines with elevated
HIF activity. To investigate this possibility, we transfected wild-
type VHL into the A498 and 786-O VHL-null cell lines. As
expected, introduction of VHL into these cell lines resulted in a
reduction in HIF-2a expression (Figure 3A) and VEGF secretion
(Figure 3B). We next evaluated the sensitivity of mock (vector only)
and VHL transfected cell lines to ELR510444. Introduction of
VHL into A498 and 786-O cells significantly reduced
ELR510444-mediated apoptosis (Figure 3C). Collectively, these
Figure 2. ELR510444 exhibits enhanced sensitivity in VHL-deficient RCC cell lines. (A) Quantification of VEGF levels in RCC cell lines. Equal
numbers of cells were plated and media was collected 16 h later. VEGF levels were measured by ELISA assay. Mean 6 SD, n=3. (B) ELR510444
reduces RCC cell viability. Cells were treated with the indicated concentrations of ELR510444 for 72 h and viability was determined by MTT assay.
Mean 6 SD, n=3. (C) ELR510444 reduces clonogenic survival. RCC cells were treated with the indicated concentrations of ELR510444 for 24 h. After
treatment, cells were washed in fresh media and allowed to grow for 10 days. Colonies were fixed and stained with crystal violet and quantified using
an Alpha Innotech gel imager. Mean 6 SD, n=3. *Indicates a significant difference compared to controls, p,0.05. (D) ELR510444 induces apoptosis.
Cells were treated with ELR510444 for 24 h and apoptosis was measured by PI-FACS analysis. Mean 6 SD, n=3. *Denotes a significant difference
compared to controls, p,0.05.
doi:10.1371/journal.pone.0031120.g002
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sensitive to ELR510444 treatment.
ELR510444 inhibits hypoxia-induced expression of HIF-2a
The effect of hypoxia on the activity of ELR510444 was
investigated in vector- and VHL-transfected A498 and 786-O
cells. Cobalt chloride (CoCl2) was used to mimic hypoxia. As
expected, the addition of CoCl2 stimulated HIF-2a expression in
the VHL-transfected cells (Figure 4A). Importantly, ELR510444
effectively reduced HIF-2a levels under both basal and hypoxic
conditions (Figure 4A). ELR510444 also reduced VEGF secretion
under hypoxic conditions and levels corresponded to HIF-2a
expression (Figure 4B). The effect of ELR510444 on cell viability
was next evaluated in vector- and VHL-transfected cell lines under
hypoxic conditions. The addition of CoCl2 did not alter the
sensitivity of vector-transfected cells (VHL
2/2) to ELR510444
(Figure 4C). However, stimulation of hypoxia enhanced
ELR510444’s activity in the VHL-transfected cells, suggesting
that ELR510444 may be more effective against cells with high
HIF activity (Figure 4C).
ELR510444 depolymerizes microtubules and arrests RCC
cells in mitosis
While 10 nM ELR510444 induced apoptosis preferentially in
VHL-null RCC cells, higher concentrations (30 nM–1000 nM)
stimulated apoptosis in RCC cells regardless of VHL status
(Figure 5A and data not shown). Analysis of cell cycle distribution
following treatment with 30 nM ELR510444 revealed that
apoptosis induction was associated with mitotic arrest
(Figure 5A). Due to the prominent M phase arrest that we
observed, we hypothesized that ELR510444 may have tubulin
binding properties. Immunocytochemistry revealed that
ELR510444 administered at concentrations as low as 20 nM
and the majority of cells at 30 nM exhibited microtubule
destabilization (Figure 5B), which is a hallmark feature of many
agents that disrupt tumor vasculature. The microtubule-destabi-
lizing drug vincristine was used as a positive control. To further
evaluate the microtubule-binding properties of ELR510444, we
investigated whether this agent interacts with the colchicine-
binding site. Using a method based on the ability of the chemical
EBI to form adducts with b-tubulin, we determined that
ELR510444 interacts with the colchicine-binding site by occupy-
ing this site and preventing EBI: b-tubulin adduct formation
(Figure 5C). Taken together, the effects of ELR510444 on HIF
expression and microtubule destabilization suggest that
ELR510444 possesses both anti-angiogenic and vascular disrupt-
ing properties.
ELR510444 reduces tumor burden in RCC xenografts
To further investigate the anticancer activity of ELR510444, we
evaluated its efficacy in the 786-O and A498 RCC mouse
xenograft models. 786-O and A498 tumor-bearing animals were
randomized into groups and given 8 mg/kg ELR510444 orally for
2 weeks on a QDx5 (every day for 5 days) schedule. Treatment
with ELR510444 significantly decreased mean tumor volume in
both xenograft models compared to the vehicle-treated controls
(Figure 6A). Importantly, ELR510444 was very well tolerated as
no significant animal weight loss was observed throughout the
duration of the study (Figure 6B). Further analysis of tumors
harvested at the end of the study revealed a significant reduction in
tumor cell proliferation as measured by PCNA staining (Figure 6C)
and an increase in cleaved caspase-3 levels, a marker of apoptosis
(Figure 6D). Collectively, these data demonstrate that ELR510444
has significant in vivo activity in RCC tumor models.
Inhibition of angiogenesis and enhanced central tumor
necrosis are associated with the antitumor activity of
ELR510444
Our in vitro studies demonstrated that ELR510444 reduced
HIF-1a and HIF-2a expression and destabilized microtubules. We
next investigated the effects of ELR510444 treatment on central
tumor necrosis, a marker of vascular disruption, and tumor
angiogenesis. Hematoxylin and Eosin (H&E) staining revealed
Figure 3. VHL-deficient cells are hypersensitive to ELR510444-
induced apoptosis. (A) HIF-2a is reduced in A498 and 786-O cells
transfected with VHL. Cells were transfected with empty vector or VHL.
Positively transfected cells were selected by incubation with puromycin.
HIF-2a was measured by immunoblotting. (B) VEGF levels are reduced
in the presence of VHL. Cells were plated and media was collected 16 h
later. VEGF levels were measured by ELISA assay. Mean 6 SD, n=3.
*Indicates a significant difference compared to controls, p,0.05. (C)
A498/VHL and 786-O/VHL cells are less sensitive to ELR510444-
mediated apoptosis. Cells were treated with 10 nM ELR510444 for
24 h and apoptosis was measured by PI-FACS analysis. Mean 6 SD,
n=3. *Represents a significant difference compared to ELR510444-
treated vector-only transfected cells, p,0.05.
doi:10.1371/journal.pone.0031120.g003
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A498 tumors treated with ELR510444 (Figure 7A). Immunohis-
tochemistry was performed to evaluate the impact of ELR510444
on microvessel density. ELR510444 treatment significantly
reduced mean vessel density as measured by CD31 staining
(Figure 7B). Dual staining of CD31 and TUNEL determined that
ELR510444 stimulated the apoptosis of tumor endothelial cells
(Figure 7C). Consistent with our in vitro data, ELR510444
treatment led to a strong decrease in VEGF levels (Figure 7D).
Our data demonstrate that ELR510444 inhibits angiogenesis,
disrupts tumor vasculature, and induces apoptosis in RCC
xenograft models.
Figure 4. ELR510444 antagonizes CoCl2-induced HIF and VEGF expression and has activity under hypoxic conditions. (A) HIF-2a is
reduced in A498 and 786-O cells treated with ELR510444. Vector- and VHL-transfected cells were treated with 10 nM ELR510444 in the presence or
absence of 250 mM CoCl2 for 24 h. HIF-2a was measured by immunoblotting. (B) VEGF levels are reduced by ELR510444. Cells were plated and treated
with 10 nM ELR510444 6 250 mM CoCl2. 16 h later, media was collected and VEGF levels were measured by ELISA assay. Mean 6 SD, n=3. (C) A498/
VHL and 786-O/VHL cells are more sensitive to ELR510444 under hypoxic conditions. Cells were treated with the indicated concentrations of
ELR510444 for 72 h 6 250 mM CoCl2. Cell viability was measured by MTT assay. Mean 6 SD, n=3.
doi:10.1371/journal.pone.0031120.g004
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e31120Figure 5. ELR510444 arrests RCC cells in mitosis and depolymerizes microtubules. (A) RCC cells were treated with 10 and 30 nM
ELR510444 for 24 h. Cell cycle distribution was determined by PI-FACS analysis. Representative histograms and the percentage of cells in each phase
of the cell cycle are shown for each experimental condition. (B) RCC4 cells were plated on chamber slides and treated for 24 h with the indicated
concentrations of ELR510444 or 100 nM vincristine. Cells were stained with a b-tubulin antibody and microtubules were visualized using an Alexa
Fluor 488-conjugated secondary antibody. Nuclei were counterstained using DAPI. The percent microtubule depolymerization was determined at
each concentration visually in 100 cells. Representative images are shown. (C) ELR510444 interacts with the colchicine-binding site of b-tubulin. RCC4
cells were pre-treated with the indicated concentrations of ELR510444 for 2 h. 100 mM EBI was then given for an additional 1.5 h. Cells were
harvested for immunoblotting and blots were probed with a b-tubulin antibody to detect native b-tubulin and EBI: b-tubulin adducts.
doi:10.1371/journal.pone.0031120.g005
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e31120Figure 6. ELR510444 reduces tumor burden and cell proliferation and stimulates apoptosis. (A) 786-O and A498 cells (1610
7/mouse)
were injected into the flanks of nude mice. When tumors reached approximately 150 mm
3 in size, mice were randomized into groups and treated on
a QDx5 schedule with 8 mg/kg ELR510444 for 2 weeks. Tumor volume was measured twice weekly. Mean 6 SEM, n=10. *Indicates a significant
difference compared to vehicle, p,0.05. (B) ELR510444 was well tolerated in vivo. Animal body weight was measured throughout the study to
quantify drug-induced weight loss. Mean 6 SD, n=10. (C) ELR510444 reduces tumor cell proliferation. PCNA levels were determined by conducting
immunohistochemistry on tumor sections. Positive cells were scored manually. Mean 6 SD, n=5. *Indicates a significant difference compared to
controls (vehicle), p,0.05. (D) ELR510444 induces apoptosis. Apoptosis was measured by cleaved caspase-3 staining. Quantification was conducted
by manually counting positive cells. Mean 6 SD, n=5. *Indicates a significant difference compared to controls (vehicle), p,0.05.
doi:10.1371/journal.pone.0031120.g006
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were stained with H&E to visualize necrosis. Percent necrosis was calculated using ImageJ software. Mean 6 SD, n=5. *Indicates a significant
difference compared to controls (vehicle), p,0.05. (B) ELR510444 reduces microvessel density. Immunohistochemistry was performed using CD31
antibody to visualize vessels. Mean vessel number was quantified manually in 5 independent sections. *Represents a significant difference compared
to controls (vehicle), p,0.05. (C) ELR510444 induces endothelial cell death. Tumor sections were stained with CD31 followed by TUNEL assay. CD31-
TUNEL-positive cells were counted manually. Mean 6 SD, n=5. *Indicates a significant difference compared to controls (vehicle), p,0.05. (D)
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HIFs are frequently overexpressed in a broad range of tumor
types, including renal, breast, and head and neck cancers and
often correlate with poor clinical prognosis [1,2,3,4,5,6,16,24,25].
Since elevated HIF expression promotes tumor progression,
inhibition of HIF activity is a promising approach to treat cancer.
This strategy may be especially effective against RCCs that have
constitutive HIF activity due to the loss of VHL expression.
Consistent with this idea, temsirolimus and everolimus, which are
both approved for RCC therapy, have been shown to reduce HIF
activity by blocking mTOR activation [26,27]. Other agents with
anti-angiogenic activity including sunitinib and vorinostat have
also displayed an ability to reduce HIF expression and possess
efficacy against RCC [27,28]. While these agents have displayed
activity in RCC, drug resistance is a significant problem, thus
highlighting the need for new therapies.
Several other agents that have been identified as HIF-1a
inhibitors including YC-1, PX-12, and PX-478 have exhibited
efficacy in both in vitro and in vivo tumor models, further validating
HIF as a therapeutic target [29,30,31]. Our results show that
ELR510444 decreases HIF-1a and HIF-2a expression, inhibits
angiogenesis, and depolymerizes microtubules via interaction with
the colchicine-binding site on b-tubulin. ELR510444 also
demonstrated promising activity in RCC xenografts in vivo, which
was associated with decreased angiogenesis and enhanced
necrosis. The ability of this agent to decrease both HIF-1a and
HIF-2a levels combined with its anti-angiogenic and anti-vascular
properties suggest that it may have significant efficacy against
highly vascularized tumors such as RCC. Vascular-directed
therapies that target both angiogenesis and the pre-existing
vasculature may yield enhanced antitumor activity as compared
with agents that specifically target new or intrinsic vessels.
Consistent with this idea, an earlier study demonstrated that co-
treatment of bevacizumab with the vascular disrupting agents
combretastatin A4 phosphate (Zybrestat) or combretastatin A1
phosphate (OXi4503) produced significantly improved anticancer
activity compared to single agent therapy [32].
Investigation of the efficacy of ELR510444 in a panel of RCC
cell lines revealed that it displayed preferential efficacy in RCC
cells lacking functional VHL. Furthermore, introduction of wild-
type VHL into VHL-deficient cells conferred resistance to
ELR510444-mediated apoptosis. Interestingly, a previously con-
ducted study demonstrated that VHL-deficient cells were also
more sensitive to the mTOR inhibitor temsirolimus/CCI-779
[33]. These observations indicate that cells lacking VHL may be
hypersensitive to agents that block HIF activity. Since inactivation
of VHL is frequently observed in RCC, it may be possible to
exploit this phenomenon therapeutically.
In addition to decreasing HIF expression, ELR510444 also
depolymerizes microtubules at higher concentrations. The ability
of ELR510444 to disrupt microtubules has recently been reported
in other cell types as the drug was found to bind to the colchicine-
binding site of b-tubulin, which is similar to other vascular
disrupting agents such as the combretastatins [34]. Our data
supports this finding as we also show that ELR510444 interacts
with the colchicine-binding site of b-tubulin in RCC cells. This
suggests that ELR510444 targets the pre-existing vasculature as
well as new vessel formation. Similar to ELR510444, 2-
methoxyestradiol (2-ME) decreases HIF-1a and HIF-2a levels
and depolymerizes microtubules [35,36]. 2-ME has demonstrated
activity against various cancer models, but displayed limited
bioavailability in clinical trials [37,38,39]. Analogs of 2-ME
designed to improve its stability and efficacy are currently in
development.
Recent work has described HIF-independent functions of VHL
demonstrating that it is a microtubule-binding protein that
promotes microtubule stability [40]. Further studies showed that
VHL inhibited nocodazole-induced microtubule depolymeriza-
tion, reduced microtubule turnover, and enhanced stability by
decreasing mitotic catastrophe [40,41]. Since VHL promotes
microtubule stability, VHL-deficient cells may be more prone to
cell death induced by ELR510444 or other microtubule
depolymerizing agents. It is possible that this activity also
contributes to the efficacy of ELR510444 in VHL-null RCC.
ELR510444 is a promising new agent that warrants further
investigation for the treatment of RCC and other malignancies
that display elevated HIF activity. Collectively, our data establish
that ELR510444 decreases HIF-1a and HIF-2a expression,
inhibits angiogenesis, possesses vascular disrupting properties,
and provide the foundation for future clinical investigation of
ELR510444.
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